Another hypertension visit

Aaron M. Tejani; Jacky T.P. Siu; Jim M. Wright; Ken Bassett; Vijaya Musini; Barbara Mintzes; Tom Perry

In their response to our letter,¹ Campbell et al state why they do not agree with our opinions² regarding intensive blood pressure treatment in patents with type 2 diabetes. Our opinions were first presented in response to their recent update on the management of hypertension in patients with type 2 diabetes.³

It is interesting to note that no competing interests were declared by the authors of the recent letter by Campbell et al.¹ The authors might have not understood the question but, through a quick search of the Internet, it is clear that all the authors, except Dr Chockalingam and Ms Morris, have disclosed (in recent publications) perceived or actual conflicts of interest with several different pharmaceutical companies who manufacture antihypertensive medications.^3–7 We equate these conflicts with “competing interests” and think it is important for readers to be aware of this information while interpreting the work of Campbell et al. We strongly believe that readers could be misled by their original declaration and would respectfully suggest that a correction be published immediately.

Footnotes

Competing interests

None declared

References

↵
1. Campbell NRC,
2. Gilbert RE,
3. Leiter LA,
4. Larochelle P,
5. Tobe S,
6. Chockalingam A,
7. et al
. Hypertension revisited [Letters]. Can Fam Physician 2012;58:635-6.
OpenUrl
↵
1. Siu JTP,
2. Tejani AM,
3. Musini V,
4. Bassett K,
5. Mintzes B,
6. Wright J
. Hypertension control in patients with diabetes [Letters]. Can Fam Physician 2012;58:30-5.
OpenUrl FREE Full Text
↵
1. Campbell NRC,
2. Gilbert RE,
3. Leiter LA,
4. Larochelle P,
5. Tobe S,
6. Chockalingam A,
7. et al
. Hypertension in people with type 2 diabetes. Update on pharmacologic management. Can Fam Physician 2011;57:997-1002, e347-53. Eng. (Fr).
OpenUrl Abstract/FREE Full Text
1. Dunford E,
2. Webster J,
3. Woodward M,
4. Czernichow S,
5. Yuan WL,
6. Jenner K,
7. et al
. The variability of reported salt levels in fast foods across six countries: opportunities for salt reduction. CMAJ 2012;184(9):1023-8. Epub 2012 Apr 16.
OpenUrl Abstract/FREE Full Text
1. Cardiometabolic Risk Working Group: Executive Committee
. Cardiometabolic risk in Canada: a detailed analysis and position paper by the Cardiometabolic Risk Working Group. Can J Cardiol 2011;27(2):e1-33.
OpenUrl CrossRef PubMed
1. Canadian Cardiovascular Society
. CCS conflicts of interest guidelines and disclosure statements. 2006 CCS Heart Failure Consensus Conference disclosure statements. Ottawa, ON: Canadian Cardiovascular Society; 2006. Available from: www.hfcc.ca/downloads/important_notices/Disclosure_Statements.pdf. Accessed 2012 Jul 9.
↵
1. Charrois TL,
2. McAlister FA,
3. Cooney D,
4. Lewanczuk R,
5. Kolber MR,
6. Campbell NR,
7. et al
. Improving hypertension management through pharmacist prescribing; the rural Alberta clinical trial in optimizing hypertension (Rural RxACTION): trial design and methods. Science 2011;6:94.
OpenUrl